GLP-1 receptor agonists hold key market opportunities due to their effectiveness in diabetes and obesity management, expanding to cardiovascular and neurodegenerative disorders. Innovations like oral ...

GLP-1s are changing the menu landscape for restaurants as diners fundamentally change how they eat. Here's what you'll start ...

The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of ...

Recent studies show GLP-1s tied higher osteoporosis risk, with variations by diabetes status and weight changes in large patient datasets.

Point32Health has yet to operate in the black since it merged the state’s second- and third-largest insurers, Harvard Pilgrim ...

Maybe if the health insurance and pharmaceutical industries weren’t such grifters, people wouldn’t have to turn to alternatives.” ...

Hims & Hers (HIMS) stock falls as the FDA send warning letters to telehealth firms that illegally market low-cost compounded ...

As more patients take GLP-1 medications, it’s common for patient questions to arise about how alcohol consumption may affect ...

Combining GLP-1 medications with 8 healthy lifestyle habits reduced the risk of major adverse cardiovascular events, or MACE, ...

Hims & Hers remains a 'Strong Buy' at $16, with fair value estimated at $22 despite recent headwinds. Click here to read an analysis of HIMS stock now.

Meta-analysis of 64 clinical trials 'should give clinicians and their patients more confidence,' say Hopkins researchers ...